Atripla

From Proteopedia

Jump to: navigation, search

A fixed-dose triple combination of emtricitabine, tenofovir and efavirenz (Sustiva, marketed by Bristol-Myers Squibb) was approved by the U.S. Food and Drug Administration (FDA) on July 12, 2006, under the brand name Atripla.

Proteopedia Page Contributors and Editors (what is this?)

Alexander Berchansky

Personal tools